Physician profile
Carl Tahn
NPI 1508961319
$12,547.88
in general payments reported to CMS, 2019-2025
71 companies · $1,892 in 2025
The $1,892 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,783 · 2020: $1,683 · 2021: $1,332 · 2022: $370 · 2023: $1,734 · 2024: $3,754 · 2025: $1,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,206 · Consulting Fee: $2,975 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,206.35 |
| Consulting Fee | $2,975.00 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,003.55 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| Taiho Oncology, INC. | $1,479.86 | 2019-2025 | |
| Astellas Pharma US INC | $578.34 | 2019-2024 | Xospata |
| Glaxosmithkline, LLC. | $524.00 | 2020-2025 | Ojjaara, Blenrep |
| Pfizer INC. | $464.68 | 2019-2025 | |
| Janssen Biotech, INC. | $449.37 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $420.15 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Scientific Affairs, LLC | $400.38 | 2021 | |
| Novartis Pharmaceuticals Corporation | $383.39 | 2019-2025 | |
| Abbvie INC. | $331.17 | 2019-2025 | Venclexta |
| Sanofi-Aventis U.S. LLC | $300.00 | 2020 | |
| Tersera Therapeutics LLC | $294.77 | 2019-2025 | Zoladex |
| Ipsen Biopharmaceuticals, INC | $293.07 | 2019-2025 | Onivyde |
| Regeneron Healthcare Solutions, INC. | $277.76 | 2019-2025 | Libtayo |
| Genzyme Corporation | $275.00 | 2020-2024 |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $267.01 | 2019-2025 | Iclusig, Vonvendi |
| Stemline Therapeutics INC. | $227.83 | 2023-2025 | Orserdu |
| Daiichi Sankyo INC. | $221.28 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Sobi, INC | $218.10 | 2022-2025 | |
| Emd Serono, INC. | $171.47 | 2020-2025 | |
| Gilead Sciences, INC. | $170.58 | 2021-2025 | Trodelvy |
| Amgen INC. | $161.49 | 2019-2023 | Kyprolis, Nplate, Vectibix |
| Eisai INC. | $161.36 | 2019-2025 | |
| Incyte Corporation | $157.14 | 2019-2025 | Jakafi, Monjuvi |
| Jazz Pharmaceuticals INC. | $141.74 | 2019-2025 | |
| Genentech USA, INC. | $128.69 | 2019-2025 | Tecentriq, Polivy, Phesgo |
| Lilly USA, LLC | $128.10 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $113.33 | 2019-2025 | |
| Tesaro, INC. | $110.82 | 2019 | |
| Seagen INC. | $103.95 | 2021-2023 | Padcev, Tukysa |
| Exelixis INC. | $100.92 | 2019-2025 | Cabometyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.50 | 2019-2023 | Gilotrif |
| Pharmacyclics LLC, An Abbvie Company | $92.65 | 2019-2023 | Epkinly |
| Aveo Pharmaceuticals, INC. | $90.82 | 2023-2024 | Fotivda |
| Pharmaessentia USA Corporation | $85.80 | 2023-2025 | Besremi |
| Puma Biotechnology, INC. | $84.64 | 2019-2025 | |
| Genmab U.S., INC. | $66.68 | 2024-2025 | Tivdak |
| Rigel Pharmaceuticals, INC. | $64.09 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Celgene Corporation | $62.12 | 2019-2021 | |
| Novocure INC. | $59.70 | 2025 | Optune Lua (Novottf-200t) |
| Sumitomo Pharma America, INC. | $59.20 | 2023-2025 | Orgovyx |
| Servier Pharmaceuticals LLC | $56.18 | 2023-2025 | |
| Tempus Ai, INC | $44.51 | 2024 | Xt Cdx |
| Syndax Pharmaceuticals, INC. | $41.61 | 2025 | |
| Amag Pharmaceuticals, INC. | $40.09 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $37.62 | 2019 | |
| Sun Pharmaceutical Industries INC. | $37.19 | 2025 | |
| Dova Pharmaceuticals | $35.60 | 2019-2021 | |
| Blueprint Medicines Corporation | $34.74 | 2022-2023 | Ayvakit |
| Kite Pharma, INC. | $32.92 | 2025 | Yescarta |
| E.R. Squibb & Sons, L.L.C. | $30.93 | 2023-2025 | Opdivo |
| Springworks Therapeutics, INC. | $23.38 | 2025 | Ogsiveo |
| Clovis Oncology, INC. | $23.14 | 2019 | |
| Novo Nordisk INC | $22.30 | 2022 | |
| Myriad Genetic Laboratories, INC. | $21.87 | 2024 | Myrisk |
| Boston Scientific Corporation | $19.76 | 2025 | Spaceoar Vue System - 10ml |
| Azurity Pharmaceuticals, INC. | $17.85 | 2025 | Danziten |
| Epizyme, INC. | $17.29 | 2021 | |
| Legend Biotech USA INC. | $17.22 | 2025 | Carvykti |
| Myovant Sciences INC. | $16.89 | 2021 | |
| Apellis Pharmaceuticals, INC. | $16.55 | 2025 | Empaveli |
| Alexion Pharmaceuticals, INC. | $15.61 | 2019 | |
| Foundation Medicine, INC. | $15.34 | 2020 | |
| Array Biopharma INC | $13.84 | 2019 | |
| Immunogen, INC. | $13.75 | 2024 | Elahere |
| Tolmar, INC. | $13.34 | 2024 | |
| Karyopharm Therapeutics INC. | $13.26 | 2022 | |
| G1 Therapeutics, INC. | $13.11 | 2023 | Cosela |
| Morphosys, US INC. | $13.02 | 2021 | |
| Agios Pharmaceuticals, INC. | $13.00 | 2019 | |
| Mylan Institutional INC. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Tahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.